Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SRF114 |
| Synonyms | |
| Therapy Description |
SRF114 is a monoclonal antibody that targets CCR8, which potentially induces antibody-dependent cellular cytotoxicity against CCR8-expressing T-regulatory cells and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2020;8; Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SRF114 | SRF-114|SRF 114|CHS-114|CHS114|CHS 114 | CCR8 Antibody 13 | SRF114 is a monoclonal antibody that targets CCR8, which potentially induces antibody-dependent cellular cytotoxicity against CCR8-expressing T-regulatory cells and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2020;8; Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05635643 | Phase Ib/II | SRF114 + Toripalimab-tpzi SRF114 | Study of CHS-114 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |